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ORIGINAL ARTICLE
Background/Aims: Serum ferritin is a marker of acute phase reactions and iron storage. In addition, hematologic
malignancies are associated with elevated serum ferritin levels. Other studies have suggested that ferritin is a
surrogate for advanced disease and has an impact on relapse, because elevated serum ferritin predicts overall
survival (OS) and relapse-free survival following autologous stem cell transplantation for lymphomas.
Methods: We studied 89 consecutive patients with newly diagnosed multiple myeloma to determine the value of
serum ferritin in comparison with known prognostic factors.
Results: The OS in the elevated serum ferritin group (≥300 ng/mL) was shorter than that in the normal serum
ferritin group (<300 ng/mL, p<0.001) after a median follow-up of 25 months. In univariate analysis, elevated
ferritin was correlated with poor survival in the patients (relative risk [RR], 2.588; 95% confidence interval [CI],
1.536 to 4.358; p<0.001). Furthermore, multivariate analysis showed that elevated serum ferritin was an
independent predictor of mortality in patients with multiple myeloma (RR, 2.594; 95% CI, 1.403 to 4.797; p=0.002).
Conclusions: The serum ferritin can a prognostic parameter of survival as well as disease activity in patients
with multiple myeloma. (Korean J Intern Med 2009;24:368-373)
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INTRODUCTION
Multiple myeloma (MM) is a plasma cell dyscrasia
characterized by the slow proliferation of malignant
plasma cells, primarily in the bone marrow. Several prog-
nostic parameters are correlated with survival in patients
with MM; these include β-2-microglobulin (B2MG), C-
reactive protein (CRP), lactate dehydrogenase (LDH), the
bone marrow plasma cell percentage (BMPC), albumin,
creatinine, hemoglobin, performance status, and conven-
tional cytogenetics [1-4].
Elevated levels of serum ferritin, the most widely used
surrogate marker for iron storage, are associated with
worse outcomes following transplantation for acute
leukemia and myelodysplastic syndrome [5]. In addition,
elevated pre-transplantation ferritin levels were associated
with relapse following autologous hematopoietic stem
cell transplantation for lymphoma [6]. A recent study
reported that the serum ferritin level was increased in
hematologic malignancies [7].
No study has examined whether the serum ferritinlevel
reflects the outcome in MM. Therefore, we measured the
serum ferritin levels in newly diagnosed MM patients to
determine whether the level is correlated with outcome
and is an independent predictor of survival in patients
with MM.
METHODS
Patient population
Eighty-nine consecutive patients with MM seen atSong MK, et al. Serum ferritin as a prognostic factor in multiple myeloma    369
Pusan National University Hospital between 2000 and
2006 were evaluated retrospectively. There were 46 males
and 43 females, and their median age was 64 years (range,
38 to 87). The median follow-up duration was 24 months
(range, 16 to 72). At the time of diagnosis, most patients had
been treated with single first-line chemotherapy regimens,
although some patients had been treated with multiple
chemotherapy regimens. Thirteen patients underwent
Table 1. Patient chracteristics according to the serum ferritin level 
Serum ferritin level
Characteristic All ≥300 ng/mL <300 ng/mL p value
(n=39) (n=50)
Age, yr 64 (50-87) 65 (38-84) 0.814
≥65 43 (48.3) 17 (19.1) 26 (29.2) 0.433
<65 46 (51.7) 22 (24.7) 24 (30.0)
Albumin, g/L
≥3.5 35 (39.3) 10 (11.2) 25 (28.1) 0.020
<3.5 54 (60.7) 29 (32.6) 25 (28.1)
B2MG, µg/mL
≥3.5 58 (65.2) 30 (33.7) 28 (31.5) 0.041
<3.5 29 (34.8) 9 (10.1) 22 (24.7)
BMPC, %
≥40 38 (42.7) 31 (34.8) 7 (7.9) <0.001
<40 51 (57.3) 8 (9.0) 43 (48.3)
Calcium, mg/dL 9.3 (6.1-15.2) 9.2 (7.2-13.5)
Creatinine, mg/dL
≥2.0 22 (24.7) 13 (14.6) 9 (10.1) 0.098
<2.0 67 (75.3) 26 (29.2) 41 (46.1)
CRP, mg/dL
≥2.0 23 (25.8) 19 (21.3) 4 (4.5) <0.001
<2.0 66 (74.2) 20 (22.5) 46 (55.1)
Hemoglobin, g/dL
≥8.0 51 (67.3) 21 (23.6) 30 (33.7) 0.563
<8.0 38 (32.7) 18 (20.2) 20 (22.5)
International staging system
Stage I 16 (18.0) 3 (3.4) 13 (14.6) 0.011
Stage II 32 (36.0) 14 (15.8) 18 (20.2)
Stage III 41 (46.0) 22 (24.7) 19 (21.3)
LDH level, IU/L
≥upper normal limit 31 (34.8) 18 (20.2) 13 (14.6) 0.008
<upper normal limit 58 (65.2) 21 (23.6) 37 (41.6)
Autologous transplantation
yes 15 (16.8) 9 (10.1) 13 (14.6) 0.355
no 74 (83.2) 30 (33.7) 37 (41.6)
Performance status (ECOG)
≥2  23 (25.8) 13 (14.6) 10 (11.3) 0.156
<2 66 (74.2) 26 (29.2) 40 (44.9)
Cytogenetics study
Normal karyotype 23 (25.8) 12 (14.7) 11 (12.4) 0.351
Abnormal karyotype 66 (74.2) 17 (19.1) 39 (43.8)
Values are number (%).
B2MG, beta-2-microglobulin; BMPC, bone marrow plasma cell percent; CRP, C-reactive protein; LDH, lactate dehydrogenase; ECOG, Eastern
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autologous stem cell transplantation (ASCT).
Prognostic factors
The known prognostic factors for patients with MM
were included in the analysis. These consist of age (≥65
years), albumin (<3.5 g/L), B2MG (≥3.5 µg/mL), BMPC
(≥40%), creatinine (≥2.0 mg/dL), CRP (≥2.0 mg/dL),
hemoglobin (<8.0 g/dL), International staging system
(ISS) stage (I to III), Eastern Cooperative Oncology Group
performance status (ECOG ≥2), conventional cytogenetics
(normal or abnormal karyotype), and ASCT. The results of
fluorescence in situ hybridization (FISH) were not
included, because FISH was performed on only 23% of
the patients.
A colorimetric enzyme-linked immunosorbent assay
was used to quantify the serum ferritin level at diagnosis.
The normal range for serum ferritin in our laboratory is
18-300 ng/mL. Therefore, the cut-off level of serum
ferritin was set at 300 ng/mL.
Table 2. Univariate analysis for overall survival
Variable Overall survival
Relative risk 95% Confidence interval p value
Age ≥65 yr 1.259 0.759-2.089 0.372
Albumin <3.5 g/L 4.634 2.482-8.653 <0.001
Hemoglobin <8.0 g/dL 0.584 0.520-0.976 0.040
β2MG ≥3.5 µg/mL 3.160 1.697-5.882 <0.001
BMPC ≥40 % 1.834 1.099-3.060 0.020
Creatinine ≥2.0 mg/dL 4.153 2.266-7.612 <0.001
CRP ≥2.0 mg/dL 2.118 1.199-3.740 0.010
LDH above the upper limit of normal 1.922 1.157-3.191 0.012
Ferritin ≥300 ng/mL 2.588 1.536-4.358 <0.001
Performance status (ECOG) ≥2 1.712 0.992-2.954 0.053
Abnormal karyotype 1.853 1.071-3.206 0.028
Autologous transplantation 0.189 0.067-0.533 0.002
Thalidomide-containing regimen 0.849 0.398-1.812 0.672
Bortezomib-containing regimen 0.993 0.749-1.317 0.964
β2MG, beta-2-microglobulin; BMPC, bone marrow plasma cell percent; CRP, C-reactive protein; LDH, lactate dehydrogenase; ECOG, Eastern
Cooperative Oncology Group.
Figure 1. Overall survival according to the International
staging system. The difference was statistically significant
(p<0.001).
Figure 2. Overall survival according to the serum ferritin level.
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Statistical analysis
The overall survival (OS) was analyzed using the Kaplan-
Meier method and measured from the date of diagnosis to
the date of death or last follow-up. The Mann-Whitney U
test was used to compare variables between the patients
with and without elevated ferritin levels. The outcomes
were estimated using the Kaplan-Meier method and
compared between patients with and without elevated
ferritin and according to the ISS stage. Cox proportional
hazards analysis was used to identify univariate and
multivariate prognostic factors for OS. The results of the
Cox proportional hazards analyses are summarized as the
hazard ratio (HR), or relative risk (RR), and 95%
confidence interval (CI) for the HR. A p value <0.05 was
considered to be statistically significant. Analyses were
performed using SPSS version 14.0 (SPSS Inc., Chicago,
IL, USA).
RESULTS
Patient characteristics
The distributions of the patients’ baseline characteristics
are presented in Table 1, according to the serum ferritin
level at the time of diagnosis.
The initial treatment regimens were as follows: 47 patient
received melphalan-prednisone; 21 patients, a thalidomide-
containing regimen (thalidomide-dexamethasone or
thalidomide-cyclophosphamide-dexamethasone); 13
patients, vincristine-adriamycin-dexamethasone and then
ASCT; and eight patients, a bortezomib-containing
regimen (bortezomib-dexamethasone).
The baseline characteristics were analyzed according to
the serum ferritin. Thirty-nine MM patients had elevated
ferritin, and 50 patients had normal ferritin levels. The
patient group with an elevated serum level was associated
with a lower albumin level, and B2MG, BMPC, CRP, and
LDH levels above the upper limits of normal, compared
with the patients with a normal ferritin level. The calcium,
creatinine, and hemoglobin levels did not differ between
the two patient groups (Table 1).
Outcome and prognostic factors
Sixty-three patients (70.8%) had died by the date of the
final analysis. The median OS times according to the ISS
stage were 39, 17, and 8 months for stages I, II, and III,
respectively.
Based on univariate analysis using a Cox proportional
model, the OS did not differ between the two age groups
in this study (<65 and ≥65 years). However, higher
albumin (p<0.001) and hemoglobin (p=0.040) levels,
normal B2MG (p<0.001), BMPC (p=0.020), creatinine
(p<0.001), CRP (p=0.010), and LDH (p=0.012) levels, an
abnormal karyotype (p<0.001), and ASCT (p=0.002)
were significantly associated with longer survival (Table
2). Furthermore, OS differed significantly according to
the ISS stage (p<0.001, Fig. 1).
Interestingly, the group with elevated serum ferritin
had poorer survival (p<0.001, Table 2 and Fig. 2). Twenty
(40%) of the 50 patients in the normal ferritin group were
alive at the end of the study, versus only seven (17.9%) of
the 39 patients in the elevated ferritin group. 
Table 3. Multivariate analysis for overall survival
Overall survival
Relative risk 95% confidence interval p value
Albumin <3.5 g/L 3.872 1.906-7.867 <0.001
Hemoglobin <8.0 g/dL 0.846 0.454-1.576 0.598
β2MG ≥3.5 µg/mL 3.196 1.594-6.406 0.001
BMPC ≥40 % 1.551 0.842-2.858 0.160
Creatinine ≥2.0 mg/dL 1.681 0.848-3.333 0.137
CRP ≥2.0 mg/dL 1.251 0.654-2.392 0.499
LDH above the upper limit of normal 1.854 1.073-3.204 0.027
Ferritin ≥300 ng/mL 2.594 1.403-4.797 0.002
Abnormal karyotype 0.961 0.520-1.777 0.900
Autologous transplantation 0.250 0.087-0.715 0.010
β2MG, beta-2-microglobulin; BMPC, bone marrow plasma cell percent; CRP, C-reactive protein; LDH, lactate dehydrogenase.372 The Korean Journal of Internal Medicine Vol. 24, No. 4, December 2009
Prognostic value of serum ferritin and other
factors
To further evaluate the prognostic value of the serum
ferritin level in patients newly diagnosed with MM, Cox
analysis was performed for ferritin and other factors.
Based on multivariate analysis, a lower albumin (p<0.001;
RR, 3.872; 95% CI, 1.906 to 7.867), higher B2MG
(p=0.001; RR, 3.196; 95% CI, 1.594 to 6.406), elevated
LDH (p=0.027; RR, 1.854; 95% CI, 1.073 to 3.204), and
elevated ferritin (p=0.002; RR, 2.594; 95% CI, 1.403 to
4.797) were independent adverse prognostic factors
associated with increased mortality. Furthermore, the
patients who underwent ASCT had lower mortality
(p=0.010; RR, 0.250; 95% CI, 0.087 to 0.715; Table 3).
DISCUSSION
The serum ferritin level reflects acute phase reactions
and is usually associated with iron storage. Iron overload
increases the susceptibility to organ damage and the risk
for infection [8,9]. Recent studies have shown that serum
ferritin is a surrogate of iron overload and is an important
predictor of survival in transplantation patients [5,6].
However, one study showed that patients with hematologic
malignancies have significantly higher serum ferritin
levels [7]. Another study showed that the intensity of the
99mTc-MIBI scan correlates with the serum ferritin level
as a marker of disease activity [10]. A third study found
that elevated serum sIL-6R levels were related to the
growth of myeloma cells and that the concentration was
an indicator of disease activity; the sIL-6R level was
correlated with the serum B2MG, CRP, ferritin, and LDH
concentrations as a marker of disease activity [11]. However,
no study has examined whether the serum ferritin level at
diagnosis is associated with the outcome in patients newly
diagnosed with MM.
The correlation between elevated ferritin levels and OS
is unclear. A recent study reported that the urinary hepcidin
level was significantly higher in MM patients than in
normal controls and that it was correlated with the serum
ferritin level [12]. The authors suggested that the growth
of myeloma was associated with hepcidin-inducing
cytokines and other mechanisms. The serum hepcidin
concentration was also elevated in patients with MM in
another study [13].
Hepcidin synthesis is pathologically increased by
inflammation [14]. Hepcidin and serum ferritin respond
similarly to inflammation and changes in iron stores, and
this is reflected by the strong correlation between hepcidin
and ferritin. Therefore, the serum ferritin level may reflect
disease activity in MM.
In this study, the patients in the elevated ferritin level
group had more adverse prognostic factors at baseline and
a poorer clinical outcome compared with patients in the
normal ferritin group. Furthermore, the serum ferritin
levels at the time of diagnosis were correlated with survival
in newly diagnosed MM patients. When the cut-off level of
serum ferritin was set at 300 ng/mL, the median OS
differed between the elevated and normal ferritin groups.
Based on univariate analysis, the elevated serum ferritin
group had a shorter survival time than the normal serum
ferritin group. In addition, lower albumin, lower hemo-
globin, higher B2MG, higher BMPC, higher creatinine,
higher CRP, elevated LDH, undergoing conventional
chemotherapy only, and an abnormal karyotype were
adverse prognostic factors. Multivariate analysis showed
that lower albumin, higher B2MG, elevated LDH, elevated
ferritin, and no ASCT were independent prognostic factors
for shorter survival in newly diagnosed MM patients.
This study has some limitations. First, a small number
of MM patients was included and evaluated retrospectively.
A prospective study with more patients should be
performed. Second, the prognosis according to FISH was
not determined and should be studied. Third, the outcomes
according to treatment regimen were not measured. This
was difficult to assess because of the many regimens
administered.
In conclusion, the serum ferritin level may be associated
with OS in patients with newly diagnosed MM. Further
investigation is warranted to determine whether serum
ferritin is an independent prognostic marker and a
measure of disease activity.
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